Intangible Assets (Details 2)	3 Months Ended	12 Months Ended						1 Months Ended	12 Months Ended					12 Months Ended		78 Months Ended	12 Months Ended		1 Months Ended		12 Months Ended	1 Months Ended	12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended
	Sep. 30, 2011 USD ($)	Dec. 31, 2012 USD ($) item	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2012 Auralis Limited	Dec. 31, 2011 Auralis Limited USD ($)	Dec. 31, 2011 Auralis Limited EUR (€)	Oct. 31, 2008 Cinryze	Dec. 31, 2012 Cinryze item	Dec. 31, 2012 Vancocin USD ($)	Sep. 30, 2012 Vancocin USD ($)	Mar. 31, 2012 Vancocin USD ($)	Dec. 31, 2011 Vancocin USD ($)	Dec. 31, 2012 Vancocin Eli Lilly And Company USD ($)	Dec. 31, 2011 Vancocin Eli Lilly And Company USD ($)	Jun. 30, 2011 Vancocin Eli Lilly And Company USD ($)	Dec. 31, 2011 Vancocin Eli Lilly And Company Minimum USD ($)	Dec. 31, 2011 Vancocin Eli Lilly And Company Maximum USD ($)	Sep. 30, 2011 Buccolam Minimum	Sep. 30, 2011 Buccolam Maximum	Dec. 31, 2012 Product Rights Auralis Limited	Oct. 31, 2008 Product Rights Cinryze	Dec. 31, 2012 Product Rights Cinryze USD ($)	Dec. 31, 2011 Product Rights Cinryze USD ($)	Dec. 31, 2012 Product Rights Buccolam USD ($)	Dec. 31, 2011 Product Rights Buccolam USD ($)	Dec. 31, 2012 Product Rights Plenadren USD ($)	Dec. 31, 2011 Product Rights Plenadren USD ($)	Dec. 31, 2012 Contract Rights Auralis Limited USD ($)	Dec. 31, 2011 Contract Rights Auralis Limited USD ($)
Finite-Lived Intangible Assets Disclosures
Exclusivity period for orphan drug																						7 years
Carrying amount of intangible asset		$ 617,539,000	$ 648,659,000							$ 113,326,000			$ 120,025,000										$ 433,606,000	$ 454,446,000	$ 5,690,000	$ 6,062,000	$ 58,088,000	$ 60,767,000	$ 6,829,000	$ 7,359,000
Useful life of acquired intangible assets beyond the orphan exclusivity period																							18 years
Useful life of acquired intangible assets beyond the data protection period for biosimilar versions																							13 years
Number of patients treated by a specific product									4,600
Number of people thought to be inflicted by HAE but not yet diagnosed									10,000
Maximum period for non-licensing of a biosimilar after first licensing of reference biologic		12 years
Number of C1 inhibitors who received approval for prophylaxis		1
Period of expected cash flows used in asset valuation process										25 years
Sales used to determine additional contingent consideration payable (as a percent)															35.00%
Sales used to determine additional contingent consideration payable																	45,000,000	65,000,000
Amount by which sum of undiscounted cash flows exceeded carrying amount											34,000,000	210,000,000
Aggregate additional purchase price consideration			7,000,000	7,000,000										116,000,000		51,100,000
Maximum sales used to determine additional contingent consideration payable															65,000,000
Acquisition of Auralis Limited					May 28, 2010
Useful life of acquired intangible assets								25 years		25 years											10 years		25 years		10 years		10 years		12 years
Remaining estimated useful life of intangible asset										17 years
Age of children and adolescents for the purpose of being eligible for treatment																			3 months	18 years
Non-cash asset impairments	8,495,000		8,495,000			8,500,000	5,400,000
Amortization expense		$ 35,301,000	$ 31,035,000	$ 29,357,000